|
시장보고서
상품코드
2032877
응급피임약 시장 보고서 : 유형별, 유통 채널별, 지역별(2026-2034년)Emergency Contraceptive Pills Market Report by Type (Combination Pills, Progesterone Pills, and Others), Distribution Channel (Retail Stores, Online Stores, and Others), and Region 2026-2034 |
||||||
세계의 응급피임약 시장 규모는 2025년에 6억 2,660만 달러에 이르렀습니다. IMARC Group은 향후 2034년까지 시장 규모가 8억 3,860만 달러에 이를 전망이며, 2026-2034년 CAGR 3.19%로 성장할 것으로 예측했습니다. 피임과 가족계획에 대한 대중의 인식 증가, 정부 및 비정부기구(NGO)의 지원책 시행, 최근 비호르몬형 응급피임약(ECP)의 개발 등이 시장을 견인하는 주요 요인으로 작용하고 있습니다.
응급피임약(ECP)은 원치 않는 임신을 예방하기 위해 사용되는 피임약을 말합니다. 이들은 배란을 지연시키고 자궁내막의 상태를 변화시켜 수정을 방해하는 레보노르게스트렐과 같은 합성 호르몬을 사용하여 제조됩니다. ECP는 전통적인 피임법이 실패했을 때, 무방비 성관계 후, 정기적인 피임약 복용을 잊어버렸을 때, 성범죄 피해자들이 백업으로 널리 사용되고 있습니다. 이들은 안전하고 비용 효율적이며, 쉽게 구할 수 있고, 장기적인 불임 문제를 일으키지 않고 의도파관 않은 임신을 효과적으로 예방하고 낙태의 필요성을 없애는 매우 편리한 약품입니다. 또한, ECP는 생식 건강 관리를 개선하고, 여성의 임파워먼트를 촉진하며, 불안과 스트레스를 줄이고, 부작용을 최소화하는 데 도움을 줍니다.
응급피임약 시장 동향 :
피임과 가족계획에 대한 대중의 인식이 높아지는 것은 시장 성장을 이끄는 주요 요인 중 하나입니다. ECP는 원치 않는 임신을 예방하고, 프라이버시를 보호하며, 부작용과 향후 합병증의 위험을 최소화하는 안전하고 편리하며 매우 편안한 응급 피임법으로 여성들 사이에서 널리 사용되고 있습니다. 또한, 무방비 성관계 및 성폭행으로 인한 의도치 않은 임신 발생률 증가에 따른 제품의 광범위한 사용도 시장 성장을 가속하는 요인으로 작용하고 있습니다. 또한, 정부 및 비정부기구(NGO)의 인식 제고, 대중 교육, 응급피임약에 대한 접근성을 높이기 위한 지원책이 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한, 체내 프로게스테론 수용체를 차단하고 기존 레보노르게스트렐 계열 정제에 비해 부작용이 적은 우프리스탈 아세테이트를 함유한 비호르몬성 응급피임약(ECP)의 최근 동향이 시장 성장에 탄력을 받고 있습니다. 이 외에도 전 세계적으로 여성의 건강과 웰빙에 대한 관심이 높아짐에 따라 제품 채택이 확대되고 있는 것도 시장 성장을 견인하고 있습니다. 이와 더불어 처방전이 필요 없고 응급상황 시 여성들이 쉽게 구할 수 있는 일반의약품(OTC)에 대한 수요 증가도 시장 성장을 뒷받침하고 있습니다. 또한, 제조업체들의 소셜 미디어, 인플루언서 마케팅, TV 광고, 유명인사 기용을 통한 적극적인 홍보 및 브랜딩 캠페인도 시장 성장에 기여하고 있습니다. 이 밖에도 소비자의 구매력 향상, 활발한 연구개발(R&D) 활동, EC 플랫폼을 통한 제품 접근성 등이 시장 성장을 견인할 것으로 예측됩니다.
목차
제1장 서문
제2장 조사 범위 및 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 응급피임약 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 유통 채널별
제8장 시장 내역 : 지역별
제9장 촉진요인, 억제요인 및 기회
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
AJY 26.05.19The global emergency contraceptive pills market size reached USD 626.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 838.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.19% during 2026-2034. The increasing awareness among the masses regarding contraception and family planning, the implementation of supportive policies by governments and non-governmental organizations (NGOs), and the recent development of non-hormonal ECPs represent some of the key factors driving the market.
Emergency contraceptive pills (ECPs) refer to birth control medications used for preventing unwanted pregnancies. They are manufactured using synthetic hormones, such as levonorgestrel, which delays ovulation, changes the linings of the uterus, and prevents egg fertilization. ECPs are widely used during the failure of traditional methods of contraception, after unprotected sexual intercourse, as a backup for missing routine birth control pills, and by the victims of sexual assault crimes. They are safe, cost-effective, accessible, and highly convenient medications that do not cause long-term fertility issues, successfully prevent unintended pregnancies, and eliminate the need for abortions. ECPs also provide better control over reproductive health, empower women, reduce anxiety and stress, and minimize side effects.
EMERGENCY CONTRACEPTIVE PILLS MARKET TRENDS:
The increasing awareness among the masses regarding contraception and family planning is one of the key factors propelling the market growth. ECPs are widely used by women as a safe, convenient, and highly comfortable form of emergency contraception, which prevents unwanted pregnancies, maintains privacy, and minimizes the risks of side effects and future complications. Along with this, the widespread product utilization due to rising incidences of unintended pregnancies owing to unprotected intercourse and sexual assault is acting as another growth-inducing factor. Furthermore, the implementation of supportive policies by governments and non-governmental organizations (NGOs) to spread awareness, educate the masses, and provide easy access to emergency contraception is positively influencing the market growth. Additionally, the recent development of non-hormonal ECPs, which contains ulipristal acetate that blocks progesterone receptors in the body and produces fewer side effects compared to traditional levonorgestrel-based pills, is providing an impetus to the market growth. Apart from this, the rising product adoption owing to the increasing focus on women's health and well-being across the globe is favoring the market growth. Besides this, the growing demand for over-the-counter (OTC) products that don't require prescriptions and can be easily accessed by women in case of emergency is supporting the market growth. Moreover, aggressive promotional and branding campaigns by manufacturers through social media, influencer marketing, television (TV) commercials, and celebrity endorsement are contributing to the market growth. Other factors, including rising expenditure capacities of consumers, extensive research and development (R&D) activities, and easy product availability across e-commerce platforms, are anticipated to drive the market growth.
KEY MARKET SEGMENTATION:
Type Insights:
- Combination Pills
- Progesterone Pills
- Others
Distribution Channel Insights:
- Retail Stores
- Online Stores
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for emergency contraceptive pills. Some of the factors driving the North America emergency contraceptive pills market included the increasing awareness regarding women's health, supportive government policies, and significant technological advancements.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global emergency contraceptive pills market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Afaxys Pharma LLC, Foundation Consumer Healthcare LLC, Gedeon Richter Plc, HLL Lifecare Limited, Perrigo Company plc, Piramal Enterprises Ltd., Syzygy Healthcare Solutions LLC, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Emergency Contraceptive Pills Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Combination Pills
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Progesterone Pills
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Retail Stores
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Online Stores
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
- 9.1 Overview
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Afaxys Pharma LLC
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.2 Foundation Consumer Healthcare LLC
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Gedeon Richter Plc
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 HLL Lifecare Limited
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.5 Perrigo Company plc
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Piramal Enterprises Ltd.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.7 Syzygy Healthcare Solutions LLC
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.1 Afaxys Pharma LLC
